KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBIT Margin (2016 - 2025)

Pacific Biosciences Of California has reported EBIT Margin over the past 16 years, most recently at 92.28% for Q4 2025.

  • Quarterly results put EBIT Margin at 92.28% for Q4 2025, up 29786.0% from a year ago — trailing twelve months through Dec 2025 was 346.15% (down 3818.0% YoY), and the annual figure for FY2025 was 346.15%, down 3818.0%.
  • EBIT Margin for Q4 2025 was 92.28% at Pacific Biosciences Of California, up from 101.13% in the prior quarter.
  • Over the last five years, EBIT Margin for PACB hit a ceiling of 92.28% in Q4 2025 and a floor of 1154.51% in Q1 2025.
  • Median EBIT Margin over the past 5 years was 179.56% (2021), compared with a mean of 252.04%.
  • Peak annual rise in EBIT Margin hit 37549bps in 2025, while the deepest fall reached -94487bps in 2025.
  • Pacific Biosciences Of California's EBIT Margin stood at 179.56% in 2021, then crashed by -77bps to 318.37% in 2022, then soared by 53bps to 150.02% in 2023, then crashed by -160bps to 390.14% in 2024, then skyrocketed by 76bps to 92.28% in 2025.
  • The last three reported values for EBIT Margin were 92.28% (Q4 2025), 101.13% (Q3 2025), and 112.79% (Q2 2025) per Business Quant data.